Salix’s Future Prospects Could Hinge On Audit Of Inventory Reporting
This article was originally published in The Pink Sheet Daily
Executive Summary
CFO resigns and audit committee starts review of inventory stocking as Salix concedes wholesalers have closer to nine months of Xifaxan and other products in the channels, rather than the ideal three-month’s worth. Share price tumbles as Wall Street puzzles on how to properly value the GI specialist.